Lizheng Shi
assistant professor

Department(s):
Health Systems Management

Email:
lshi1@tulane.edu

Research Interests:
Pharmaceutical and health care economics; pharmacoepidemiology; health care quality, access, and evaluation

Professional Achievements:
1998-present Member, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
2001-present Member, International Society for Bipolar Disorders (ISBD)
2002-present Member, ISPOR Contributed Research Abstract Review Committee
2003-present Judge for ISPOR Contributed Research Poster and Podium Presentations
2004-present Elected member, Collegium International Neuro-Psychopharmacologicum (CINP)
2008 Outstanding Reviewer, Pharmacoepidemiology and Drug Safety

Educational Background:
BS, Pharmacy, Shanghai Medical University, China
MS, Pharmacy, Peking Union Medical College, China
MA, Economics, University of Southern California
PhD, Pharmacy, Economics and Policy, University of Southern California

Publications:
Shi L, Hodges M, Drummond M, Ahn J, Li SC, Hu S, Augustovski F, Hay JW, Smeeding J. Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report-Part VI. Value Health. 2009 Oct 26.

Fonseca VA, Smith H, Kuhadiya N, Leger SM, Yau CL, Reynolds K, Shi L, McDuffie RH, Thethi T, John-Kalarickal J. Impact of a Natural Disaster on Diabetes: Exacerbation of Disparities and Long-term Consequences. Diabetes Care. 2009 Jun 19. [Epub ahead of print]

Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet Med. 2008 Aug;25(8):924-32.

Ahn J, McCombs JS, Jung C, Croudace TJ, McDonnell D, Ascher-Svanum H, Edgell ET, Shi L. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid Program. Value Health 2008 Jan/Feb;11(1):48-56.

Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 2007 Apr;58(4):437.

McCombs JS. Ahn J, Tencer T, Shi L. The impact of unrecognized bipolar disorders among patients treated for depression with antidepressants in the fee-for-services California medicaid (Medi-Cal) program: a six-year retrospective analysis. J Affect Disord 2006 Jul.

Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler, R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med 2006;36:1535-1540.

Shi L, Juarez R, Hackworth J, Edgell ET, Harro JM, Vieta, E, Tohen M. Open-label olanzapine treatment in bipolar I disorder: clinical and work functional outcomes. Curr Med Res Opin 2006;22:961–966.

Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-1129.

Kessler RC, Birnbaum H, Demler O, Falloon RH, Gagnon E, Guyer M, Howes MJ, Kendler KS, Shi L, Walters E, Wu, EQ. The prevalence and correlates of non-affective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry 2005;58: 668–676.

Tunis SL, Zhu B, Zhao Z, Baker RW, Lage MJ, Shi L, Tohen M. Effectiveness and costs of olanzapine versus divalproex treatment for acute mania: Results from a randomized clinical trial. Curr Med Res Opin 2005;21(4):555-584.

Shi L, Thiebaud P, McCombs JS. The impact of unrecognized bipolar disorders for patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program. J Affect Dis 2004;82:373-383.

Namjoshi MA, Risser R, Shi L, Tohen M, Breier A. Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. J Affect Dis 2004;81:223-229.

Shi L, Schuh L, Trzepacz PT, Namjoshi M, Huang L, Namjoshi M, Tohen M. Improvement of positive and negative syndrome Scale (PANSS) cognitive score associated with olanzapine treatment of acute mania. Curr Med Res Opin 2004;20(9):1371-1376.

Shi L, Namjoshi M, Swindle R, Yu X, Risser R, Baker RW, Tohen M. Effects of olanzapine alone and olanzapine/fluoxetine combination (OFC) on health-related quality of life in patients with bipolar depression: secondary analysis of a double blind, placebo-controlled trial. Clin Ther 2004;26(1):125-134.

Contact Information:
Lizheng Shi, PhD, MsPharm
Department of Health System Management
Tulane University School of Public Health and Tropical Medicine
New Orleans, LA 70112
Tel: 504-988-6548
Fax: 504-988-3783

Level of Instruction:
graduate